UNCY
Unicycive Therapeutics Inc

3,057
Mkt Cap
$133.25M
Volume
446,396.00
52W High
$11.00
52W Low
$3.71
PE Ratio
-1.91
UNCY Fundamentals
Price
$6.20
Prev Close
$6.08
Open
$6.10
50D MA
$6.23
Beta
0.63
Avg. Volume
670,592.85
EPS (Annual)
-$5.65
P/B
3.45
Rev/Employee
$0.00
$27.83
Loading...
Loading...
News
all
press releases
Analysts Set Expectations for UNCY FY2030 Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Analysts at HC Wainwright issued their FY2030 earnings per share estimates for Unicycive Therapeutics in a research report issued on Monday...
MarketBeat·19d ago
News Placeholder
More News
News Placeholder
Unicycive Resubmits NDA For Oxylanthanum Carbonate To FDA
(RTTNews) - Unicycive Therapeutics, Inc. (UNCY) on Monday said it has resubmitted its New Drug Application (NDA) to the U.S. Food and Drug Administration for oxylanthanum carbonate (OLC) for the...
Nasdaq News: Markets·2mo ago
News Placeholder
Vivo Capital LLC Has $5.42 Million Stock Position in Unicycive Therapeutics, Inc. $UNCY
Vivo Capital LLC lowered its position in shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) by 90.0% in the second quarter, according to its most recent 13F filing with the Securities...
MarketBeat·2mo ago
News Placeholder
Unicycive Therapeutics (NASDAQ:UNCY) Trading Up 5.6% - Time to Buy?
Unicycive Therapeutics (NASDAQ:UNCY) Trading 5.6% Higher - Time to Buy...
MarketBeat·2mo ago
News Placeholder
UNCY FY2025 EPS Boosted by Brookline Capital Management
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Research analysts at Brookline Capital Management boosted their FY2025 EPS estimates for Unicycive Therapeutics in a research report issued...
MarketBeat·3mo ago
News Placeholder
HC Wainwright Has Positive Outlook for UNCY FY2029 Earnings
Unicycive Therapeutics, Inc. (NASDAQ:UNCY - Free Report) - Research analysts at HC Wainwright boosted their FY2029 EPS estimates for Unicycive Therapeutics in a research note issued to investors on...
MarketBeat·3mo ago
News Placeholder
Unicycive Therapeutics (NASDAQ:UNCY) Releases Quarterly Earnings Results, Beats Expectations By $0.29 EPS
Unicycive Therapeutics (NASDAQ:UNCY - Get Free Report) announced its quarterly earnings data on Wednesday. The company reported ($0.33) earnings per share for the quarter, beating the consensus...
MarketBeat·3mo ago
News Placeholder
UNCY Deadline Today: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their Rights
Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of purchasers of securities of Unicycive Therapeutics, Inc. (NASDAQ: UNCY) between March...
Business Wire·4mo ago
News Placeholder
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY
Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCY Unicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the...
PR Newswire·4mo ago
News Placeholder
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive Therapeutics
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Unicycive Therapeutics, Inc. (Unicycive or the Company) (NASDAQ: UNCY) and reminds investors of...
Business Wire·4mo ago
<
1
2
...
>

Latest UNCY News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.